| Literature DB >> 27134470 |
Dinesh M Bramhane1, Preethi A Kulkarni1, Elvis A F Martis2, Raghuvir R S Pissurlenkar2, Evans C Coutinho2, Mangal S Nagarsenker1.
Abstract
AIMS: The objective of present study was to study the influence of different β-cyclodextrin derivatives and different methods of complexation on aqueous solubility and consequent translation in in vivo performance of Pioglitazone (PE).Entities:
Keywords: Anti-diabetic activity; hydroxypropyl-β-cyclodextrin; pioglitazone; sulfobutylether-7-β-cyclodextrin; β-cyclodextrin
Year: 2016 PMID: 27134470 PMCID: PMC4832908 DOI: 10.4103/0975-7406.171680
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
Abbreviations used to designate different complexes
Figure 1(a) Phase solubility curves of β-cyclodextrin-pioglitazone and hydroxypropyl-β-cyclodextrin - pioglitazone (n = 3). (b) Phase solubility curve of sulfobutylether-7-ß-cyclodextrin-pioglitazone (n = 3)
Increase in solubility of PE in presence of CD. Data expressed as mean of three determinations and RSD <5%)
Figure 2Overlay of fourier-transform infrared spectra of different pioglitazone
Figure 3The overlay of powder X-ray diffraction diffractograms of pioglitazone and various solid dispersions
Figure 4The overlay of differential scanning calorimetry thermograms of pioglitazone and various dispersions
Figure 5Graphical representation of mode of inclusion as interpreted from proton nuclear magnetic resonance
Changes in chemical Shift values of BCD protons and PE aromatic protons
Changes in chemical Shift values of HPBCD protons and PE aromatic protons
Changes in the chemical shift of aromatic proton of PE complexed with SBEBCD
Figure 6Overlay of nuclear magnetic resonance spectra of kneaded complexes
Figure 7Three-dimensional structures of the complexes of Pioglitazone with different cyclodextrins obtained by molecular docking. Case 1 and Case 2 depict the two orientations in which pioglitazone can be embedded into the cyclodextrin cavity
Summary of free energy of binding calculated from the energetic of the MD simulations for the three cyclodextrins
DE60 and DP10 values for BCD, HPBCD and SBEBCD complexes. Measurements expressed as mean of three determinations with RSD <5%
Figure 8(a) Preprandial changes in blood glucose levels (n = 6). (b) Postprandial changes in blood glucose levels (n = 6)